[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100593727":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":10,"centralContacts":31,"locations":37,"responsibleParty":53,"collaborators":10,"id":57,"slug":10,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":60,"acronym":10,"eligibilityCriteria":61,"healthyVolunteers":62,"sex":63,"minAge":64,"maxAge":10,"enrollmentInfo":65,"targetDuration":10,"studyType":68,"phases":10,"briefSummary":69,"conditions":70,"keywords":72,"overallStatus":40,"whyStopped":10,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Zhongshan People's Hospital, Guangdong, China","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"HCC Screening Dynamic Cohort",null,"Local household-registered residents aged 35-64 years who are HBsAg-positive and have not been diagnosed with HCC prior to enrollment, residing in the study site communities of Zhongshan City",[13,14,15],"Diagnostic Test: Quantitative HBeAg Testing","Biological: Measurement Indicators Required for Risk Scoring in HCC Screening Strategies","Biological: Follow-Up Monitoring Parameters",[17,22,27],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":10},"DIAGNOSTIC_TEST","Quantitative HBeAg Testing","Quantitative HBeAg Testing in Population-Based Primary Screening",[9],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":10},"BIOLOGICAL","Measurement Indicators Required for Risk Scoring in HCC Screening Strategies","REACH-B: Age, Sex, HBeAg status, ALT levels, and HBV DNA load; AGED: Age, Sex, HBeAg status, HBV DNA load; aMAP: Age, Sex, Albumin, Total Bilirubin, Platelet Count; aMAP 3.0: Age, Sex, Albumin, Total Bilirubin, Platelet Count, AFP and PIVKA-II.",[9],{"type":23,"name":28,"description":29,"armGroupLabels":30,"otherNames":10},"Follow-Up Monitoring Parameters","AFP, Liver Ultrasound",[9],[32],{"name":33,"role":34,"phone":35,"phoneExt":10,"email":36},"Mingfang Ji, MD","CONTACT","86-0760-89880417","jmftbh@sina.com",[38],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Zhongshan People's Hospital","RECRUITING","Zhongshan","Guangdong","528403","China",{"type":46,"coordinates":47},"Point",[48,49],113.37912,22.52306,{"lat":49,"lon":48},[52],{"name":33,"role":34,"phone":35,"phoneExt":10,"email":36},{"type":54,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Mingfang Ji","Clinical Professor","100593727",false,"NCT07010198","Head-to-Head Comparison of Hepatocellular Cancer (HCC) Screening Strategies: A Prospective Population-Based Cohort Study in Zhongshan City","Inclusion Criteria:\n\n* Voluntarily sign the informed consent form.\n* Household registration in Zhongshan City, Guangdong Province.\n* Aged 35 and above.\n* Positive screening result for Hepatitis B surface antigen (HBsAg).\n\nExclusion Criteria:\n\n* Previous history of liver cancer or liver transplantation.\n* Pregnant women.\n* Severe comorbidities (e.g., end-stage cardiopulmonary diseases, advanced malignancies).\n* Individuals lacking legal capacity or unable to provide informed consent.",true,"ALL","35 Years",{"count":66,"type":67},4500,"ESTIMATED","OBSERVATIONAL","Based on the preliminary retrospective validation of the efficacy of five HCC screening strategies(including conventional AFP combined with ultrasound-based general screening strategy, REACH-B, AGED, aMAPand aMAP 3.0 risk score) in Xiaolan Town, a head-to-head comparison for HCC screening is conducted in Zhongshan City, Guangdong Province. The study is a prospective, single-center, head-to-head trial aiming to enroll 4,500 HBsAg-positive individuals. It adopts a two-phase design of \"HBV screening first, followed by HCC surveillance\":Phase I: Recruitment of age-eligible populations at study sites for HBsAg screening to establish a high-risk cohort positive for hepatitis B surface antigen.Phase II: Implementation of uniform HCC surveillance (AFP combined with liver ultrasound every six months) for HBsAg-positive individuals, with concurrent application of different risk stratification models to evaluate risk levels and screening efficacy for each participant during follow-up.Furthurmore, based on baseline biological information and follow-up data, the study also aims to explore the development of a more effective risk prediction model for HCC.",[71],"Hepatocellular Cancer (HCC)",[73,74,75],"Screening","Hepatocellular Cancer","aMAP","2025-05-29",{"date":78,"type":79},"2025-06-08","ACTUAL",{"date":81,"type":79},"2025-03-01",{"date":83,"type":67},"2028-12-31",{"name":5,"class":6},1]